Is Ozempic covered by insurance in Canada?

If you have type 2 diabetes, most Canadian public and private plans will cover a GLP-1 drug with some paperwork. If you want one for weight loss, you are very likely paying for it yourself — public plans essentially never cover that indication, and only about a third of employer plans do. That's not for lack of a process: a national review came close to changing it for Wegovy specifically in 2025, before the manufacturer walked away from the price negotiation that would have made it real.

The short version

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are approved prescription drugs in Canada, and every public and private drug plan in the country draws the same basic line: type 2 diabetes is a covered indication, weight management generally is not. That split shows up identically whether you're looking at a provincial formulary or an employer benefits plan — the diabetes dose gets a path to coverage with conditions attached; the weight-management dose is, for almost everyone, a cash purchase. A generic diabetes-dose semaglutide arriving in 2026 has meaningfully lowered the floor price for people paying out of pocket, but it hasn't changed who gets covered for what.

What the provinces will pay for — and won't

Every province with public drug coverage treats GLP-1 drugs the same way in substance, even where the paperwork differs: covered for a documented type 2 diabetes diagnosis, after you've tried a cheaper first-line drug (almost always metformin) and it hasn't worked or can't be used — and not covered at all for weight management.

Other provinces follow the same pattern under their own program names — Alberta, Saskatchewan, Manitoba and the Atlantic provinces each run some version of a special-authorization or exception-drug process gating GLP-1 coverage to a documented type 2 diabetes diagnosis, and none currently reimburses the weight-management dose.

A national recommendation came close in 2025 — then the manufacturer walked away

The gap described above isn't for lack of a process. Canada's Drug Agency (CDA-AMC, the federal body that reviews drugs for public-plan reimbursement, formerly branded CADTH) issued a formal recommendation in July 2025 that Wegovy be reimbursed — not for "weight loss" broadly, but for a specific, narrower population: adults with a BMI of 27 kg/m² or higher who also have pre-existing cardiovascular disease (a prior heart attack, stroke, or similar), alongside a reduced-calorie diet and increased physical activity, with coverage past the first year conditional on documenting at least a 5% reduction in BMI or body weight. The recommendation came with one hard condition attached: reimbursement only if Novo Nordisk substantially cut the price. CDA-AMC's own cost modelling put public plans' exposure at up to roughly $600 million over three years at the drug's list price, rising toward $3.5 billion depending on how many eligible patients actually took it up — and pointed negotiators toward seeking a discount in the neighbourhood of 67% off list price as a starting position.

That set up a real negotiation, not a formality. The pan-Canadian Pharmaceutical Alliance (pCPA) — the body that negotiates drug prices on behalf of every federal, provincial and territorial public plan at once, rather than each running its own talks — sent Novo Nordisk a formal letter of engagement on 2 October 2025. Novo Nordisk declined to participate: no counter-offer was ever exchanged, and on 1 December 2025 the pCPA closed the file without an agreement. A company spokesperson, Kate Hanna, said Novo Nordisk had decided not to pursue public reimbursement "at this time." pCPA's chief executive, Mauro Chies, said the door remains open: "We remain ready and available to re-engage this file should they change their mind." As of this review, that re-engagement hasn't happened, and the practical result for anyone in Canada today is the one described throughout this page — no public plan pays for Wegovy for weight loss, not because a regulator said no, but because the one party that could set a negotiable price chose not to offer one. None of this touches Ozempic's own, separate diabetes-indication reimbursement, which was never part of this file.

Quebec runs its own separate process — and has said no twice

The stalled federal file above isn't Quebec's only brush with a Wegovy reimbursement decision. RAMQ listings for Quebec specifically also go through INESSS (Institut national d'excellence en santé et en services sociaux) — a provincial health-technology-assessment body that runs its own separate review, in parallel with rather than instead of the federal pCPA/CDA-AMC process described above. INESSS evaluated two separate Wegovy submissions in 2025 and recommended against reimbursing both.

The first, received 22 September 2025, sought reimbursement for Wegovy's effect on general cardiometabolic health in adults with a BMI of 35 kg/m² or higher — the broad weight-management population this page discusses throughout. INESSS recommended against listing it on therapeutic-value grounds, and the Health Minister's own decision, dated 4 March 2026, was not to add it to Quebec's reimbursed-medicines lists. The second, received 11 August 2025, was narrower: coverage specifically to reduce the risk of a repeat heart attack or stroke in adults with obesity and existing cardiovascular disease (BMI 27 kg/m² or higher) — the same population defined by Novo Nordisk's SELECT trial, and the same kind of narrower, cardiovascular-risk-linked group that other regulators covered on this site, including Australia's PBAC, have used as their own way into a Wegovy listing. INESSS again recommended against reimbursement, writing in its own notice to the minister that given the drug's "modest efficacy, safety concerns, disproportionate cost relative to clinical benefit, and excessive budgetary impact," listing Wegovy for this indication "is not a responsible, fair or equitable decision" — while separately acknowledging that semaglutide's cardiovascular-risk reduction is real, just modest, and could ease pressure on the health system if it were larger. Unlike the first file, the Health Minister's own decision here, dated 11 December 2025, was to defer a final call rather than issue an outright refusal.

Put next to the collapsed federal file in §2b, the practical result for Quebec residents is the same either way: no version of Wegovy is reimbursed by RAMQ for weight-related use, whether the request runs through Ottawa's pan-Canadian process or Quebec's own. If anything, Quebec's own file has gone slightly further than the stalled federal one — an actual negative recommendation and one outright refusal, not just an unresolved price negotiation.

Private and employer plans: growing, but not the norm

This is where the real movement has happened, and where the picture actually looks different from the public side — just not different enough to call it "typical" yet. The International Foundation of Employee Benefit Plans (IFEBP) has surveyed Canadian employers on GLP-1 coverage every year since 2024, and the trend is a steady expansion of weight-loss coverage alongside a steady decline in plans that cover diabetes only: 66% covered diabetes-only in 2024; by 2026 that had fallen to 51%, while weight-loss coverage rose from 31% (2025) to 37% (2026), plus a further 12% covering other conditions such as sleep apnea or cardiovascular disease.

Even so, 54% of surveyed employers said in 2026 they weren't considering weight-loss coverage at all, with only 17% actively considering adding it. The reason plans are cautious isn't mysterious: GLP-1 drugs made up 11.1% of Canadian employers' total annual drug claims in 2026, per the same survey — a fast-growing cost line for whoever is paying the premium, though the survey didn't collect enough responses in earlier years to establish a reliable year-over-year trend for that specific figure.

Where a plan does cover weight-loss GLP-1s, coverage almost never means "show your prescription and it's paid." The most common cost-control tool is utilization management — prior authorization, a minimum BMI (commonly 30, or 27 with a documented comorbidity like hypertension or sleep apnea), and evidence you've already tried lower-cost, non-drug approaches. A plan listing a drug as "eligible" and actually paying a specific claim are two different things if that paperwork hasn't been done in advance.

What it costs if you're paying yourself

Before any generic existed, brand-name Ozempic or Wegovy commonly ran $300 to $400 a month or more depending on dose — full stop, whether you had diabetes or not. That floor has moved for one specific product since May 2026: a generic version of semaglutide at the type 2 diabetes dosing reached Canadian pharmacies (Dr. Reddy's, approved 28 April 2026; Apotex, approved 1 May and launched 14 May 2026), pricing settling fast enough that CBC's own coverage called it "about $100 a month across the country" — most price-comparison sources put the actual range closer to roughly $90–$120/month depending on pharmacy.

Does Canada's new national pharmacare change this?

Not yet, and not for the drugs this page is about. The federal Pharmacare Act received royal assent in October 2024, and its first phase funds two categories for provinces that sign a bilateral agreement: contraception, and diabetes medications and supplies. British Columbia was first to sign and is, as of March 2026, the first province with the program actually running — its "Plan NP" pays the full cost of a defined list of diabetes drugs for any BC resident enrolled in MSP, with no deductible or dispensing fee.

Here's the part worth being precise about: BC's own published Plan NP drug list covers insulin, metformin, sulfonylureas (glyburide, gliclazide), and SGLT2 inhibitors (dapagliflozin, empagliflozin), with saxagliptin, linagliptin and pioglitazone available through Special Authority — but it does not include GLP-1 receptor agonists like semaglutide. Semaglutide for diabetes in BC still runs through the pre-existing Special Authority process described in the table above, unchanged by the new pharmacare layer. National pharmacare, at least in its current first phase, is a genuine expansion of free diabetes-drug coverage — it just isn't (yet) an expansion that reaches GLP-1s specifically, for diabetes or for weight loss.

How to find out what your plan actually covers

• If you have a public plan only: ask your prescriber whether you qualify under your province's special-authorization or exception-drug process for the diabetes indication — that's the only door that opens on the public side, and it requires your prescriber to submit documentation, not just write a prescription.
• If you have an employer plan: ask your plan administrator directly whether GLP-1 drugs are covered for weight management specifically, not just "is Ozempic on the formulary" — a drug can be listed and still be paid only for one indication.
• If you're paying cash either way: ask specifically about the generic and which dose it's approved for — the diabetes-dose generic is well established and cheap; the weight-management-dose generic is newer and less consistently stocked.
• Don't assume "approved by Health Canada" means "covered." Every drug on this page is a legitimate, approved prescription medicine. Approval and reimbursement are two separate decisions, made by two different bodies, on two different timelines — and that gap is precisely what this page is about.